机构:[a]Clinic for General Internal Medicine and Cardiology, Marienhof Katholisches Klinikum Koblenz·Montabaur, Koblenz, Germany[b]Department of Cardiology, Helmut-G.-Walther-Klinikum, Lichtenfels, Germany[c]Department of Cardiology, the 4th Hospital of Harbin Medical University, Harbin, PR China[d]Department of Cardiology, the Provincial Hospital Anhui, Hefei, PR China[e]Department of Cardiology, The Second Hospital, Jilin University, Changchun, PR China[f]Department of Internal Medicine I, Division of Cardiology, University Hospital Jena, Friedrich-Schiller-University, Jena, Germany[g]Department of Anesthesiology, Helmut-G.-Walther-Klinikum, Lichtenfels, Germany[h]Department of Cardiology, The 1st Hospital of Kunming Medical University, Kun-ming, PR China内科科室心脏内科昆明医科大学附属第一医院[i]Department of Cardiology, Wuhan N0.4 Hospital, Wuhan, PR China
Objectives: To report long-term safety and efficacy of combined percutaneous LAA and PFO/ASD closure. Methods: A retrospective study of 370 consecutive patients undergoing LAAC procedures using the Watchman (WM) device. Data were compared between 330 cases only with LAAC procedure (Group I) and 25/5 (PFO/ASD) cases with sequential procedures of LAAC and PFO/ASD closure (Group II). Results: Compared to Group I, Group II had more males (86.7% vs. 65.8%, p < 0.05) and a higher rate of stroke (33.3% vs. 10.6%, p < 0.01), but there were no statistical differences in the remaining patient characteristics. During the follow-up period, there were no significant differences between the two groups in embolism events (6.1% vs. 0%, p = 0.39), device related thrombus (5.8% vs 3.3%, p = 1.0), major bleeding (9.4% vs. 6.7%, p = 1.0) and cardiac death (3.6% vs. 0%, p = 0.61). The observed rate of all thromboembolic events by Kaplan-Meier analysis was decreased by 39.9% and 100% and the observed annual rate of bleeding was reduced by 32.9% and 57.6% in Group I and Group II, respectively. Conclusions: LAAC combined with PFO/ASD closure might be an ideal choice to prevent stroke and other thrombotic complications in patients with both NVAF and PFO/ASD.
第一作者机构:[a]Clinic for General Internal Medicine and Cardiology, Marienhof Katholisches Klinikum Koblenz·Montabaur, Koblenz, Germany[b]Department of Cardiology, Helmut-G.-Walther-Klinikum, Lichtenfels, Germany
共同第一作者:
通讯作者:
通讯机构:[*1]Department of Cardiology, Wuhan N0.4 Hospital, Wuhan, PR China
推荐引用方式(GB/T 7714):
Jiangtao Yu,Xiaoxia Liu,Junling Zhou,et al.Long-term safety and efficacy of combined percutaneous LAA and PFO/ASD closure: a single-center experience (LAAC combined PFO/ASD closure)[J].EXPERT REVIEW OF MEDICAL DEVICES.2019,16(5):429-435.doi:10.1080/17434440.2019.1604216.
APA:
Jiangtao Yu,Xiaoxia Liu,Junling Zhou,Xin Xue,Manuela Muenzel...&Shaoyong Tang.(2019).Long-term safety and efficacy of combined percutaneous LAA and PFO/ASD closure: a single-center experience (LAAC combined PFO/ASD closure).EXPERT REVIEW OF MEDICAL DEVICES,16,(5)
MLA:
Jiangtao Yu,et al."Long-term safety and efficacy of combined percutaneous LAA and PFO/ASD closure: a single-center experience (LAAC combined PFO/ASD closure)".EXPERT REVIEW OF MEDICAL DEVICES 16..5(2019):429-435